GlassScriptPhysician profile
Ami S Vaidya
NPI 1346534773
$3,628.47
in general payments reported to CMS, 2019-2025
23 companies · $532 in 2025
The $532 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,807 · 2020: $272 · 2021: $87.72 · 2022: $101 · 2023: $491 · 2024: $338 · 2025: $532.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,360.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,360.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,178.81 | 2019-2025 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $598.22 | 2019-2025 | Airsupra, Tezspire, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $293.97 | 2019-2024 | Ofev |
| Mylan Specialty L.P. | $285.24 | 2019-2024 | Yupelri |
| Genentech USA, INC. | $262.91 | 2019-2023 | Xolair |
| Regeneron Healthcare Solutions, INC. | $160.70 | 2019-2025 | Dupixent |
| Electromed, INC. | $159.73 | 2019 | |
| Insmed, INC. | $126.87 | 2021-2025 | Arikayce, Brinsupri |
| Philips North America LLC | $85.27 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $66.55 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $64.16 | 2019 | |
| Shire North American Group INC | $42.24 | 2019 | |
| Sunovion Pharmaceuticals INC. | $39.84 | 2019 | |
| Verona Pharma, INC. | $36.17 | 2025 | Ohtuvayre |
| Actelion Pharmaceuticals US, INC. | $34.75 | 2023 | Opsumit |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $33.20 | 2024 | Keytruda |
| Genzyme Corporation | $29.58 | 2019 | |
| Grifols USA, LLC | $28.66 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $28.19 | 2019 | |
| Baxter Healthcare | $21.17 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Viatris Specialty LLC | $20.07 | 2025 | Yupelri |
| Amgen INC. | $17.17 | 2022 | |
| Mallinckrodt Hospital Products INC. | $15.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ami Vaidya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.